Table 3.
IRR and protective immunity of previous SARS-CoV-2 infection against medically attended symptomatic omicron BA.4, BA.5, and XBB reinfection, stratified by time from first infection
Omicron BA.4 or BA.5 |
Omicron XBB |
||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Person-days at risk | Number of cases | Incidence per million person-days | IRR* (95% CI) | Protective immunity† (95% CI) | Person-days at risk | Number of cases | Incidence per million person-days | IRR* (95% CI) | Protective immunity† (95% CI) | ||
SARS-CoV-2-naive | 53 076 623 | 3298 | 62·1 | 1·00 (reference value) | Reference | 24 498 337 | 36 510 | 1490 | 1·00 (reference value) | Reference | |
Pre-omicron | |||||||||||
3 to <12 months | 1 708 251 | 98 | 57·4 | 0·86 (0·70 to 1·06) | 14 (−6 to 30) | 594 500 | 1107 | 1862 | 1·35 (1·26 to 1·43) | .. | |
≥12 months | 1 693 303 | 63 | 37·2 | 1·03 (0·80 to 1·33) | .. | 972 008 | 1631 | 1678 | 1·34 (1·27 to 1·41) | .. | |
Omicron BA.1 | |||||||||||
3 to <8 months | 2 102 381 | 90 | 42·8 | 0·35 (0·28 to 0·43) | 65 (57 to 72) | 194 201 | 223 | 1148 | 0·60 (0·53 to 0·68) | 40 (32 to 47) | |
≥8 months | 4 527 852 | 73 | 16·1 | 0·51 (0·41 to 0·65) | 49 (35 to 59) | 2 882 732 | 3077 | 1067 | 0·73 (0·70 to 0·76) | 27 (24 to 30) | |
Omicron BA.2 | |||||||||||
3 to <6 months | 4 791 699 | 45 | 9·4 | 0·13 (0·10 to 0·18) | 87 (82 to 90) | 2 033 272 | 850 | 418 | 0·26 (0·25 to 0·28) | 74 (72 to 75) | |
6 to <7 months | 2 893 593 | 56 | 19·4 | 0·20 (0·16 to 0·26) | 80 (74 to 84) | 928 954 | 617 | 664 | 0·42 (0·39 to 0·45) | 58 (55 to 61) | |
7 to <8 months | 5 372 227 | 61 | 11·4 | 0·26 (0·20 to 0·34) | 74 (66 to 80) | 2 819 806 | 2236 | 793 | 0·51 (0·48 to 0·53) | 49 (47 to 52) | |
≥8 months | 614 795 | 0 | 0 | .. | .. | 607 465 | 502 | 826 | 0·63 (0·57 to 0·68) | 37 (32 to 43) |
IRR=incidence rate ratio.
Adjusted for age, sex, ethnicity, housing type, calendar date, vaccination status, and days since last vaccine dose.
Negative protective immunity estimates are not presented.